← All compounds
Research use onlyNot for human consumption
Performance & Recomp
IGF-1 LR3
Long-Acting Insulin-Like Growth Factor Analog
IGF-1 LR3 is a modified, long-acting analog of insulin-like growth factor-1 (IGF-1) studied for muscle growth, recovery, nutrient partitioning, and anabolic signaling.
Trusted Quality
Quick Facts
- Long-acting analog of IGF-1
- Enhanced stability and half-life compared to native IGF-1
- Supports muscle growth and recovery
- May improve nutrient partitioning (recomposition)
- Studied for anabolic signaling and protein synthesis
- Research focused on performance and body composition applications
Research Highlights
- Shown to increase lean body mass in clinical and preclinical studies
- Supports protein synthesis and muscle cell hypertrophy
- May enhance nutrient partitioning and reduce fat mass
- Demonstrates prolonged activity due to reduced binding to IGF-binding proteins
- Potential benefits for recovery, tissue repair, and training adaptations
- Favorable safety profile in research settings
How IGF-1 LR3 Works
Binds to IGF-1 Receptors
Activates IGF-1 receptors in muscle and other tissues, stimulating anabolic signaling pathways.
Promotes Anabolic Activity
Enhances protein synthesis, cell growth, and muscle hypertrophy while supporting recovery and repair.
Longer Duration
Modified structure reduces binding to IGF-binding proteins, resulting in an extended half-life and prolonged activity in circulation.
Protocol Tips
- Administer subcutaneously, preferably in the evening
- Start with conservative dosing based on research
- Combine with proper training and nutrition for optimal results
- Monitor body composition, recovery, and performance
- Maintain consistency and adequate caloric intake
Cycle Guidance
- Typical cycle length: 8–16 weeks
- Reassess goals and response before continuation
- May be used as part of a comprehensive performance or body composition strategy
- Consider periodic breaks between cycles
- Use the lowest effective dose based on research
Ask about available vial sizes and current pricing.